ERBB2 and breast carcinoma: Similarly, our study found that CD44v persistence may be used as a prediction marker of response to therapy in patients with HER2+ breast cancer treated preoperatively with dual anti-HER2 therapy and concurrent cytotoxic chemotherapy, especially with agents that may target CSCs.